GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Valuation Rank

Oncolytics Biotech (Oncolytics Biotech) Valuation Rank


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Oncolytics Biotech Valuation Rank Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Valuation Rank
Comparable Companies
TSX:TH XCNQ:ACOG TSX:MDNA TSXV:NGEN XCNQ:METX TSXV:ARCH XCNQ:DTC TSX:EPRX TSX:BCT TSXV:MIR OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
ONC:Canada
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Website
https://www.oncolyticsbiotech.com
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.